In the last trading session, 1.45 million shares of the Prime Medicine Inc (NASDAQ:PRME) were traded, and its beta was 2.18. Most recently the company’s share price was $4.78, and it changed around $0.27 or 5.99% from the last close, which brings the market valuation of the company to $573.31M. PRME currently trades at a discount to its 52-week high of $17.20, offering almost -259.83% off that amount. The share price’s 52-week low was $4.34, which indicates that the current value has risen by an impressive 9.21% since then. We note from Prime Medicine Inc’s average daily trading volume that its 3-month average coming to 698.80K.

Prime Medicine Inc (NASDAQ:PRME) trade information

Instantly PRME has showed a green trend with a performance of 5.99% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -46.05% year-to-date, but still down -12.13% over the last five days. On the other hand, Prime Medicine Inc (NASDAQ:PRME) is -34.88% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $18, which translates to bulls needing to increase their stock price by 73.44% from its current value. Analyst projections state that PRME is forecast to be at a low of $12 and a high of $23.

Prime Medicine Inc (PRME) estimates and forecasts

Prime Medicine Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -35.23 percent over the past six months and at a 11.33% annual growth rate that is well below the industry average of 13.30%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -193.88%.

PRME Dividends

Prime Medicine Inc’s next quarterly earnings report is expected to be released in May.